Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + apatinib in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR1900025068Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib and Rivoceranib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Tongji Hospital. Primary endpoint: Size of evaluable lesion. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
pyrotinibRivoceranib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1900025068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025068.